---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000055"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:11:19.535323+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan

## Summary
- Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.
- Net income $27.2M ($0.91 diluted) vs $80.7M ($2.79) in Q3 2023; SG&A rose to $28.7M.
- Cash and investments $694.2M; 460+ U.S. reimbursement approvals secured as of October.
- JNDA filed for B-VEC in Japan; EMA decision expected before year end; French early access approved.
- Guidance: non-GAAP R&D+SG&A $115-125M for FY2024; key pipeline data due by year-end.

## SEC filing metadata
- accession: 0001711279-24-000055
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000055/0001711279-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000055/krys-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000055
- JSON: https://secwatch.observer/filing/0001711279-24-000055.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.